Innate Pharma Stock Price, News & Analysis (OTCMKTS:IPHYF)

$5.35 -0.25 (-4.46 %)
(As of 12/17/2017 01:03 AM ET)
Previous Close$5.35
Today's Range$5.35 - $5.38
52-Week Range$4.92 - $16.55
Volume5,425 shs
Average Volume2,689 shs
Market Capitalization$321.20 million
P/E RatioN/A
Dividend YieldN/A
Beta1.04

About Innate Pharma (OTCMKTS:IPHYF)

Innate Pharma logoInnate Pharma S.A., a clinical-stage biotechnology company, discovers, develops, and sells immunotherapies for cancer and inflammatory diseases in France. The company offers Lirilumab (IPH2102/BMS-986015), a human checkpoint inhibitor, which is in Phase I/II clinical trial for squamous cell carcinoma of the head and neck, as well as in Phase I and Phase II clinical trials in various combinations to treat solid and hematologic tumors; Monalizumab, an immune checkpoint inhibitor that is in Phase I/II clinical trial to treat various cancer indications, as well as in Phase I clinical trial for the treatment of solid tumors; and IPH4102, an anti-KIR3DL2 humanized antibody, which is in Phase I clinical trial for cutaneous T-cell lymphomas. It is also involved in developing IPH4301, a humanized anti-MICA/B therapeutic antibody to treat oncology; IPH52, an anti-CD39 antibody for immuno-oncology; IPH53, an anti-CD73 antibody for immuno-oncology; and IPH33, a monoclonal antibody program that targets Toll-like Receptor-3 receptor, which is an inducer of Type I IFN and pro-inflammatory cytokines; and IPH5401, a therapeutic antibody that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils. The company has licensing agreements with Bristol-Myers Squibb, Novo Nordisk A/S, and the University of Genoa. Innate Pharma S.A. was founded in 1999 and is headquartered in Marseille, France.

Receive IPHYF News and Ratings via Email

Sign-up to receive the latest news and ratings for IPHYF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:IPHYF
CUSIPN/A
Phone33-04-30-30-30-30

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$72.75 million
Price / Sales3.97
Cash Flow$0.31 per share
Price / Cash17.15
Book Value$1.77 per share
Price / Book3.02

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees154
Outstanding Shares53,920,000

Innate Pharma (OTCMKTS:IPHYF) Frequently Asked Questions

What is Innate Pharma's stock symbol?

Innate Pharma trades on the OTCMKTS under the ticker symbol "IPHYF."

Who are some of Innate Pharma's key competitors?

How do I buy Innate Pharma stock?

Shares of Innate Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Innate Pharma's stock price today?

One share of Innate Pharma stock can currently be purchased for approximately $5.35.

How big of a company is Innate Pharma?

Innate Pharma has a market capitalization of $321.20 million and generates $72.75 million in revenue each year. Innate Pharma employs 154 workers across the globe.

How can I contact Innate Pharma?

Innate Pharma's mailing address is 117 Avenue de Luminy, Marseille I0, 13009. The company can be reached via phone at 33-04-30-30-30-30 or via email at [email protected]


MarketBeat Community Rating for Innate Pharma (IPHYF)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  14 (Vote Outperform)
Underperform Votes:  13 (Vote Underperform)
Total Votes:  27
MarketBeat's community ratings are surveys of what our community members think about Innate Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Innate Pharma (OTCMKTS:IPHYF) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Innate Pharma (OTCMKTS:IPHYF) Consensus Price Target History

Price Target History for Innate Pharma (OTCMKTS:IPHYF)

Innate Pharma (OTCMKTS:IPHYF) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
8/30/2017HC WainwrightReiterated RatingBuyView Rating Details
12/5/2016Leerink SwannReiterated RatingBuyView Rating Details
(Data available from 12/17/2015 forward)

Earnings

Earnings History for Innate Pharma (OTCMKTS:IPHYF)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Innate Pharma (OTCMKTS:IPHYF) Earnings Estimates

Current Year EPS Consensus Estimate: $-1 EPS
Next Year EPS Consensus Estimate: $-0.91 EPS

Dividends

Dividend History for Innate Pharma (OTCMKTS:IPHYF)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Innate Pharma (OTCMKTS IPHYF)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Innate Pharma (OTCMKTS IPHYF) News Headlines

Source:
DateHeadline
ETFs with exposure to Innate Pharma SA : December 7, 2017ETFs with exposure to Innate Pharma SA : December 7, 2017
finance.yahoo.com - December 7 at 4:19 PM
Innate Pharma SA :IPHYF-US: Earnings Analysis: For the six months ended June 30, 2017 : November 30, 2017Innate Pharma SA :IPHYF-US: Earnings Analysis: For the six months ended June 30, 2017 : November 30, 2017
finance.yahoo.com - November 30 at 11:30 AM
Zacks Investment Research Downgrades Innate Pharma (IPHYF) to SellZacks Investment Research Downgrades Innate Pharma (IPHYF) to Sell
www.americanbankingnews.com - November 29 at 12:04 AM
Innate Pharma provides an update on LirilumabInnate Pharma provides an update on Lirilumab
finance.yahoo.com - November 23 at 2:27 AM

SEC Filings

Innate Pharma (OTCMKTS:IPHYF) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Innate Pharma (OTCMKTS IPHYF) Stock Chart for Sunday, December, 17, 2017

Loading chart…

This page was last updated on 12/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.